Log in
Billions of dollars are pouring into one long-ignored asset Goldman Sachs expects will soar in the first quarter of 2020. Go here to see hard-asset expert's #1 way to play this massive shift before it turns into a runaway train.

NYSE:KOD - Kodiak Sciences Stock Price, Forecast & News

+1.15 (+1.77 %)
(As of 01/20/2020 04:31 AM ET)
Today's Range
Now: $66.06
50-Day Range
MA: $64.80
52-Week Range
Now: $66.06
Volume241,160 shs
Average Volume338,425 shs
Market Capitalization$2.45 billion
P/E RatioN/A
Dividend YieldN/A
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Market Cap$2.45 billion
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive KOD News and Ratings via Email

Sign-up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.

Kodiak Sciences (NYSE:KOD) Frequently Asked Questions

What is Kodiak Sciences' stock symbol?

Kodiak Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "KOD."

How were Kodiak Sciences' earnings last quarter?

Kodiak Sciences Inc. (NYSE:KOD) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.00. View Kodiak Sciences' Earnings History.

When is Kodiak Sciences' next earnings date?

Kodiak Sciences is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Kodiak Sciences.

What price target have analysts set for KOD?

6 analysts have issued twelve-month target prices for Kodiak Sciences' stock. Their forecasts range from $40.00 to $115.00. On average, they anticipate Kodiak Sciences' share price to reach $86.50 in the next year. This suggests a possible upside of 30.9% from the stock's current price. View Analyst Price Targets for Kodiak Sciences.

What is the consensus analysts' recommendation for Kodiak Sciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kodiak Sciences.

What are Wall Street analysts saying about Kodiak Sciences stock?

Here are some recent quotes from research analysts about Kodiak Sciences stock:
  • 1. According to Zacks Investment Research, "Kodiak Sciences Inc. operates as a clinical stage biopharmaceutical company. It specializes in novel therapeutics to treat chronic and retinal diseases. The company's product candidates consists of KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and Uveitis, KSI-201 for treatment resistant wet AMD and KSI-401 for dry AMD which are in clinical stage. Kodiak Sciences Inc. is based in CA, United States. " (1/4/2020)
  • 2. Chardan Capital analysts commented, "We thought it notable that CMO and CDO PhD spent 10 years at unrated Roche (Genentech), including as global head of late- stage ophthalmology, where his team was responsible for pivotal studies and he headed programs such as Lucentis Port Delivery. Kodiak platform address the limitations (e.g. treatment burden) of anti-VEGF therapies (>$10.5 bn in 2018 sales). With KSI-301, Kodiak hopes to address the leading global causes of blindness, namely aging and diabetes. Despite the size of the existing anti- VEGF market, an unmet medical need exists since, after 3 years or so of treatment, patients (under optimal care) typically have vision close to or worse than when the patients started anti-VEGF treatment." (6/13/2019)

Has Kodiak Sciences been receiving favorable news coverage?

Media coverage about KOD stock has been trending positive on Monday, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kodiak Sciences earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Kodiak Sciences.

Who are some of Kodiak Sciences' key competitors?

What other stocks do shareholders of Kodiak Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Amarin (AMRN), Verizon Communications (VZ), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Cisco Systems (CSCO), Splunk (SPLK), salesforce.com (CRM) and QUALCOMM (QCOM).

Who are Kodiak Sciences' key executives?

Kodiak Sciences' management team includes the folowing people:
  • Dr. Victor Perlroth, Co-Founder, Chairman, CEO & Pres (Age 45)
  • Mr. John A. Borgeson MBA, CPA, Sr. VP & CFO (Age 57)
  • Dr. Hong Liang, Sr. VP of Discovery Medicine (Age 46)
  • Dr. Jason S. Ehrlich M.D., Ph.D., Chief Medical Officer & Chief Devel. Officer (Age 42)
  • Dr. Joel Naor M.D., MSc, MBA, VP of Clinical R&D Operations

When did Kodiak Sciences IPO?

(KOD) raised $126 million in an IPO on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers.

How do I buy shares of Kodiak Sciences?

Shares of KOD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kodiak Sciences' stock price today?

One share of KOD stock can currently be purchased for approximately $66.06.

How big of a company is Kodiak Sciences?

Kodiak Sciences has a market capitalization of $2.45 billion. View Additional Information About Kodiak Sciences.

What is Kodiak Sciences' official website?

The official website for Kodiak Sciences is http://www.kodiak.com/.

How can I contact Kodiak Sciences?

The company can be reached via phone at 650-281-0850.

MarketBeat Community Rating for Kodiak Sciences (NYSE KOD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  132
MarketBeat's community ratings are surveys of what our community members think about Kodiak Sciences and other stocks. Vote "Outperform" if you believe KOD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KOD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel